Binimetinib

Chemical formula: C₁₇H₁₅BrF₂N₄O₃  Molecular mass: 441.233 g/mol  PubChem compound: 10288191

Therapeutic indications

Binimetinib is indicated for:

Melanoma with a BRAF V600 mutation

Population group: only adults (18 years old or older)

Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Non-small cell lung cancer with a BRAF V600E mutation

Population group: only adults (18 years old or older)

Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Binimetinib is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: MEKTOVI Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈